Search

Copyright of Turkish Journal of Ophthalmology / Turk Oftalmoloji Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Purpose: To present the treatment approach to ocular complications in two cases with autosomal recessive dystrophic epidermolysis bullosa (EB) and to review the literature. Material and Method: Two teenage girls with EB, one with symblepharon (case 1) and the other with corneal opacity and vascularization (case 2) presented to our clinic. Case 1 had symblepharon, extending from the left upper eyelid to the superotemporal cornea, restricting the globe movements. During surgery, symblepharon lysis and lamellar keratectomy were followed by amniotic membrane transplantation to cover the cornea and palpebral conjunctiva. At presentation, case 2 was using artificial tears and topical cyclosporin A. The right eye had visual acuity of counting fingers, and opacity with superficial and deep vascularization in the lower third of the cornea. Topical bevacizumab and autologous serum were added to her treatment. Results: In Case 1, 63 months after surgery the eyelid margin was smooth and the eye was fully mobile. A mild symblepharon of the temporal conjunctiva in both eyes was present. Stromal thinning, superficial vascularization and opacification were significant in the temporal cornea. During the 8-month follow-up period of case 2, the visual acuity increased to 20/50. Slit-lamp examination showed a decrease in corneal opacity and vascularization. Discussion: According to our cases, alternative treatments such as amniotic membrane transplantation to treat symblepharon, and topical bevacizumab and autologous serum in intractable vascularization and opacity can be considered in cases of EB. [ABSTRACT FROM AUTHOR]

A letter to the editor is presented which discusses the study on the impact of topical bevacizumab as an adjunctive therapy for neovascularization of cornea.

Purpose: This clinical study was conducted to compare the performance of a rebound tonometer with that of the Goldmann applanation tonometer (GAT) in the measurement of intraocular pressure (IOP) and to evaluate the effect of central corneal thickness (CCT) on IOP measurement with both devices. Materials and Methods: One hundred and sixty-five healthy subjects were tested using rebound tonometer and GAT by two observers. The patients were divided into 3 groups according to CCT measurement and OHTS criteria as follows: group 1 with CCT<555 µm; group 2 with CCT 555-584 µm; and group 3 with CCT≥585 µm. Correlation analysis was performed to compare the 2 devices; paired sample t test, Bland and Altman analysis were used. Results: The mean IOP levels measured by rebound tonometer and GAT were 13.9±2.3 and 13.5±2.5 mm Hg in Group1 (p=.587), 15.76±2.7 and 15.3±3.1 mmHg in Group 2 (p=.563), and 17.76±2.6 and 18.42±3.03 mm Hg in Group 3 (p=.878), respectively. Rebound tonometry and GAT readings were strongly correlated in terms of IOP measurement in all CCT groups (r=0.78, p<.0001). Conclusions: The use of rebound tonometer is effective and safe in comparison to GAT readings. In eyes with a healthy cornea, the IOP measurements from the rebound tonometer and the GAT seemed to be similarly affected by CCT. [ABSTRACT FROM AUTHOR]